3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
7
Colorectal Neoplasms
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Rectal Neoplasms
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Glioblastoma
2
Esophageal Squamous Cell Carcinoma
2
Advanced Solid Tumors
2
von Hippel-Lindau Disease
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Adenocarcinoma
1
Solid Tumors
1
Solid Tumor, Adult
1
Solid Tumor
1
Interventions
spartalizumab
1
sintilimab
1
pyrotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Digestive System Tumor
×
spartalizumab
×
1 year
×
Clear all
NCT07053150
2025-07-08
CCGLC-018
Tongji Hospital
Phase 2
Not yet recruiting
80 enrolled